Survival Advantage Seen for A+ADV in Advanced Hodgkin Lymphoma
THURSDAY, July 14, 2022 (HealthDay News) — For patients with stage III or IV Hodgkin lymphoma, brentuximab vedotin is associated with a survival advantage, according to a study published online July 13 in the New England Journal of Medicine.Stephen M…
Learn MoreFor Blood Cancer Patients, COVID Boosters Can Bring Some Immunity
MONDAY, July 11, 2022 (HealthDay News) — In a promising development, new research has discovered that most adults with blood cancers develop at least some immunity to COVID-19 after getting booster shots.”Our findings build on the wealth of literatur…
Learn More